Dai Mengyao, Sheng Jianpeng, Zhang Qi, Wang Jianxin, Fu Qihan, Liang Tingbo
The Key Laboratory of Pancreatic Diseases of Zhejiang Province, Hangzhou, China.
The Innovation Center for the Study of Pancreatic Diseases of Zhejiang Province, Hangzhou, China.
Front Oncol. 2023 Mar 1;13:1118633. doi: 10.3389/fonc.2023.1118633. eCollection 2023.
Single-agent immune checkpoint blockade has shown no clinical benefits in pancreatic cancer. Recently, the programmed cell death protein 1 (PD-1) antibody pembrolizumab has been recommended as a treatment option for high tumor mutational burden (TMB) solid tumors based on the data from a basket trial. However, no pancreatic cancer patients were enrolled in that trial. Whether pancreatic cancer patients with high TMB respond to PD-1 blockade as well remains unclear. Here, we report a case with a partial response to single-agent immunotherapy with pembrolizumab in pancreatic cancer with high TMB after the failure of several lines of chemotherapy. This result indicates that single-agent immunotherapy may be effective in pancreatic cancer patients with high TMB. In addition, in order to understand the basic immune state of our patients, we also analyzed the changes in immune cells in peripheral blood with cytometry by time-of-flight mass spectrometry (CyTOF) before and after pembrolizumab treatment.
单药免疫检查点阻断疗法在胰腺癌中未显示出临床益处。最近，基于一项篮子试验的数据，程序性细胞死亡蛋白1（PD-1）抗体帕博利珠单抗已被推荐作为高肿瘤突变负荷（TMB）实体瘤的一种治疗选择。然而，该试验未纳入胰腺癌患者。TMB高的胰腺癌患者对PD-1阻断疗法是否也有反应仍不清楚。在此，我们报告1例胰腺癌患者，在经过多线化疗失败后，接受帕博利珠单抗单药免疫治疗后出现部分缓解。这一结果表明，单药免疫治疗可能对TMB高的胰腺癌患者有效。此外，为了解我们患者的基础免疫状态，我们还通过飞行时间质谱流式细胞术（CyTOF）分析了帕博利珠单抗治疗前后外周血免疫细胞的变化。
